Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine ...

Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely driven by ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

We came across a bullish thesis on Merck & Co., Inc. on Darius Dark Investing’s Substack. In this article, we will summarize ...

Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales ...

The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. Merck, while steadfast in its manufacturing push that aligns with the administration ...